Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00967629 · ClinicalTrials.gov registry record · Phase 1

Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy

A Phase 1 study of Diabetic Nephropathy, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT00967629: Completed Phase 1 study of Diabetic Nephropathy, sponsored by Icahn School of Medicine at Mount Sinai.

NCT00967629 is a Phase 1 study of Diabetic Nephropathy that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 20 participants, below the 11,429-participant average among 9 other Diabetic Nephropathy trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00967629, a Phase 1 study of Diabetic Nephropathy, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether oral sevelamer carbonate binds advanced glycation end products (AGEs) in the gastrointestinal (GI) tract of patients with diabetic nephropathy leading to decrease body AGE load and therefore decreases the inflammation and oxidative stress in these patients.

Primary Outcome

To compare the effect of Sevelamer Carbonate versus calcium carbonate on serum AGE levels in patients with stage II-IV chronic kidney disease resulting from diabetic nephropathy from baseline to 2 months and to 4 months later.

Conditions Studied

Interventions

  • DRUG Calcium Carbonate
  • DRUG Sevelamer Carbonate

Study Locations (1)

New York

  • Mount Sinai School of Medicine - New York

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2009-06
Est. Completion 2010-02
Phase Phase 1

What the finished NCT00967629 record still lists

NCT00967629 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 11,429-participant average among 9 other Diabetic Nephropathy trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Diabetic Nephropathy appearing as the primary indexed condition, and to 2 interventions - of which Calcium Carbonate is the first listed.

NCT00967629 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00967629 about?

NCT00967629 is a clinical study titled "Effect of Sevelamer Carbonate on Oxidative Stress in Patients With Diabetic Nephropathy". The purpose of this study is to determine whether oral sevelamer carbonate binds advanced glycation end products (AGEs) in the gastrointestinal (GI) tract of patients with diabetic nephropathy leading to decrease body AGE load and therefore decreases the inflammation and oxidative stress in these pa...

What is the current status of trial NCT00967629?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2009-06. Estimated completion is 2010-02.

What conditions does trial NCT00967629 study?

This clinical trial studies the following conditions: Diabetic Nephropathy.

What interventions are being tested in trial NCT00967629?

The interventions under investigation include: Calcium Carbonate (DRUG), Sevelamer Carbonate (DRUG).

Who is sponsoring clinical trial NCT00967629?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00967629 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetic Nephropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00967629's enrollment target sits among peer trials

20 9th of 9 higher than 1 of 9 other Diabetic Nephropathy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetic Nephropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00967629, the US trial registry maintained by the National Library of Medicine. NCT00967629 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.